Subbject Index to Volume 19

24-hour urine, 19(9): 652 – 658.

68-Ga-dotatate PET/CT, 19(11): 816 – 819.

Abdominal fat segmentation, 19(10): 693 – 699.

Abdominal pain, 19(3): 225 – 228.

Abrupt, 19(1): 75 – 77.

Academic medical centers, 19(12): 832 – 837.

Acute myeloid leukemia (AML), 19(5): 379 – 380.

Acutely ill patients, 19(9): 639 – 644.

Adherence, 19(10): 704 – 711.

Adiponectin, 19(4): 269 – 274.

Adipose tissue, 19(8): 597 – 600.

Adolescent, 19(11): 797 – 804.

Adolescents, 19(8): 530 – 537.

Advanced adrenal cell carcinoma, 19(9): 671 – 673.

Afghans in Iran, 19(10): 735 – 740.

AIDS, 19(5): 329 – 334.

Alternative healthy eating index, 19(11): 752 – 761.

Alzheimer´s disease, 19(6): 449 – 452; 19(2): 101 – 109.

Amniotic membrane, 19(9): 612 – 617.

Anatomic anomaly, 19(4): 285 – 287.

Anesthesia, 19(4): 262 – 268.

Angiogenesis, 19(8): 584 – 587.

Anthropometric indices, 19(5): 342 – 347.

Anthropometry, 19(9): 631 – 638.

Antibiotic resistance, 19(5): 353 – 358.

Antibiotic susceptibility, 19(12): 866 – 869.

Antibiotic, 19(3): 204 – 209.

Anticancer, 19(11): 779 – 785.

Antihypertensive, 19(2): 110 – 115.

Anxiety, 19(4): 257 – 261.

Aortic arch, 19(1): 72 – 74.

Apolipoprotein V, 19(1): 46 – 50.

Apoptosis, 19(4): 275 – 281.

Appendectomy, 19(1): 57 – 63.

Art therapy, 19(1): 51 – 56.

Asphyxia, 19(5): 312 – 316.

Attempted suicide, 19(8): 571 – 576.

Autoimmunity, 19(8): 544 – 550.

Behavioral impairment, 19(5): 363 – 375.

Berberine, 19(3): 197 – 203.

Betamethasone, 19(9): 612 – 617.

Biological Markers, 19(10): 680 – 686.

Biomarker, 19(6): 420 – 425; 19(9): 645 – 651.

Bladder cancer, 19(9): 645 – 651.

Bladder, 19(5): 376 – 378.

Blood cancer, 19(11): 779 – 785.

Blood donors, 19(3): 192 – 196.

BMI, 19(3): 210 – 214.

BMT, 19(9): 674 – 676.

Body weight, 19(4): 282 – 284.

Bone marrow, 19(6): 388 – 396; 19(8): 584 – 587.

Brachiocephalic trunk, 19(1): 72 – 74.

Brachytherapy, 19(3): 186 – 191.

Breast cancer, 19(6): 420 – 425; 19(6): 430 – 438.

Breast Neoplasms, 19(10): 680 – 686; 19(11): 812 – 815.

BTD mutations, 19(11): 774 – 778.

Calcitriol, 19(9): 631 – 638.

Carcinoid tumor, 19(2): 150 – 152.

Cardiopulmonary bypass, 19(2): 147 – 149.

Cardiovascular disease, 19(5): 359 – 362.

Cardiovascular event, 19(2): 82 – 86.

Carpal tunnel surgery, 19(4): 285 – 287.

Carpal tunnel syndrome, 19(4): 285 – 287.

Case-control, 19(3): 166 – 172.

Caviglia GP, 19(12): 886.

Celiac disease, 19(11): 762 – 767.

Cell surface histo-blood group antigens, 19(1): 35 – 38.

Cell therapy, 19(2): 131 – 136; 19(6): 388 – 396.

Chemotherapy, 19(4): 297 – 299.

Child, 19(11): 797 – 804.

Children, 19(1): 57 – 63; 19(11): 762 – 767; 19(6): 397 – 402; 19(8): 530 – 537.

Cholangiopancreatography pancreatitis (PEP) Indomethacin, 19(8): 538 – 543.

Choroid plexus, 19(8): 561 – 570.

Chronic anemia, 19(1): 75 – 77.

Cirrhosis, 19(2): 131 – 136.

Clustering, 19(2): 101 – 109.

CMFDA, 19(6): 426 – 429.

Cognition disorders, 19(4): 257 – 261.

Cognitive tests, 19(4): 257 – 261.

Cohort Studies, 19(10): 680 – 686.

Colon, 19(4): 297 – 299.

Colorectal carcinoma, 19(1): 23 – 29.

Comb sign, 19(3): 225 – 228.

Complication, 19(5): 317 – 322.

Computed tomography, 19(5): 376 – 378.

Consanguinity, 19(10): 720 – 728.

Consciousness, 19(3): 215 – 220.

Coronary heart disease, 19(5): 359 – 362.

Critical limb ischemia, 19(6): 388 – 396.

Crohn’s disease Burden, 19(1): 2 – 15.

Crohn’s disease, 19(3): 225 – 228.

Cutaneous leishmaniasis, 19(2): 153 – 162.

Cyst, 19(3): 221 – 224.

Cystatin C, 19(12): 845 – 851.

Cytomegalovirus (CMV), 19(10): 700 – 703.

Cytoscape v: 3.2.1., 19(2): 101 – 109.

DALY, 19(4): 241 – 247.

DatSCAN, 19(6): 449 – 452.

DAVID bioinformatics resources, 19(2): 101 – 109.

DDQ, 19(9): 659 – 665.

Decision making, 19(12): 832 – 837.

Dementia diagnosis rate, 19(12): 838 – 844.

Dementia, 19(12): 838 – 844.

Demodex folliculorum, 19(3): 210 – 214.

Depression, 19(4): 257 – 261.

Developmental, 19(3): 221 – 224.

Diabetes mellitus, 19(6): 414 – 419.

Diabetes type 2, 19(3): 166 – 172.

Diagnosis, 19(5): 312 – 316.

Diet, 19(3): 166 – 172.

Dietary habits, 19(8): 530 – 537.

Dietary pattern, 19(3): 166 – 172; 19(4): 248 – 256.

Differential diagnosis, 19(6): 449 – 452.

Diphtheria, 19(6): 382 – 387.

Disease, 19(11): 762 – 767.

Disorder, 19(5): 363 – 375.

Dopaminergic, 19(8): 561 – 570.

Dosimetric characteristics, 19(3): 186 – 191.

Drainage, 19(3): 173 – 178.

Drug craving, 19(9): 659 – 665.

Dysphonia, 19(2): 87 – 91.

Early-onset, 19(12): 866 – 869.

Earthquake, 19(6): 409 – 413.

Eclampsia, 19(1): 57 – 63.

Economic consequence, 19(11): 805 – 811.

Ectopic liver, 19(1): 78 – 79.

Education, 19(6): 439 – 445.

Empiric therapy, 19(3): 204 – 209.

Endoscopic retrograde cholangiopancreatography (ERCP), 19(8): 538 – 543.

Epidemic typhus, 19(10): 747 – 750.

Evidence-based medicine, 19(8): 556 – 560.

Exercise, 19(10): 704 – 711.

Exoenzyme S, 19(5): 353 – 358.

Exotoxin A, 19(5): 353 – 358.

Externalizing, 19(1): 51 – 56.

Extracellular fraction, 19(11): 779 – 785.

Familial Mediterranean fever, 19(3): 225 – 228.

FANCA, 19(4): 236 – 240.

FANCG, 19(4): 236 – 240.

Fanconi Anemia, 19(4): 236 – 240.

Farsi, 19(10): 704 – 711; 19(9): 659 – 665.

Fasting blood glucose, 19(8): 588 – 596.

Fasting insulin, 19(8): 588 – 596.

Fatal suicide, 19(8): 571 – 576.

Fatty liver, 19(4): 282 – 284.

Fecal calprotectin, 19(3): 225 – 228.

Fee splitting, 19(12): 861 – 865.

Female genital mutilation, 19(11): 805 – 811.

Fentanyl, 19(3): 225 – 228.

Fine needle aspiration, 19(2): 150 – 152.

Flow cytometry, 19(6): 426 – 429.

FMPA, 19(6): 426 – 429.

Follow-up visit, 19(8): 551 – 555.

Food frequency questionnaire, 19(3): 166 – 172; 19(9): 652 – 658.

Food insecurity, 19(4): 288 – 294.

Framingham risk score, 19(12): 845 – 851.

Functional dyspepsia, 19(2): 123 – 130.

Gallbladder, 19(1): 78 – 79.

Gastric cancer prevention, 19(2): 137 – 140.

Gastroenteritis, 19(9): 625 – 630.

Gene expression, 19(6): 420 – 425.

Gene panel sequencing, 19(4): 236 – 240.

Gene rearrangement, 19(9): 625 – 630.

General population, 19(10): 693 – 699.

General ward, 19(9): 639 – 644.

Genes, 19(5): 363 – 375.

Genital warts, 19(10): 715 – 719.

Ginsenoside-Rh2, 19(1): 23 – 29.

Glasgow coma scale, 19(3): 215 – 220.

Global Burden of Disease (GBD), 19(4): 241 – 247.

Global burden of disease study 2010 (the GBD 2010), 19(11): 768 – 773.

Global burden of disease, 19(5): 329 – 334.

Glucose Intolerance, 19(8): 577 – 583.

Glycemic control, 19(8): 588 – 596.

Golestan cohort study, 19(11): 752 – 761.

Governing body, 19(12): 832 – 837.

Gut, 19(3): 197 – 203.

GVHD, 19(9): 674 – 676.

Gynecology, 19(3): 173 – 178.

HbA1c diabetes mellitus, 19(8): 588 – 596.

Health knowledge, 19(10): 715 – 719.

Health of migrants, 19(10): 735 – 740.

Health promoting lifestyle (HPL), 19(12): 824 – 831.

Health services, 19(1): 39 – 45.

Healthcare providers (HcPrs), 19(12): 824 – 831.

Heat stress, 19(9): 618 – 624.

Helminthes, 19(8): 608 – 609.

Hemangiosarcoma, 19(11): 812 – 815.

Hemicolectomy, 19(4): 297 – 299.

Hemodynamics, 19(4): 262 – 268.

Hemoglobin A1c, 19(6): 414 – 419.

Hemosiderosis, 19(2): 96 – 100.

HER-2 polymorphism, 19(6): 430 – 438.

Hereditary hearing loss, 19(10): 720 – 728.

Heroin, 19(9): 659 – 665.

History of medicine, 19(10): 747 – 750; 19(2): 153 – 162.

History, 19(8): 608 – 609.

HIV, 19(3): 192 – 196; 19(5): 329 – 334.

Hormone therapy, 19(2): 141 – 146.

HPLC, 19(6): 414 – 419.

hs-CRP, 19(5): 348 – 352.

HSCT, 19(9): 674 – 676.

Human capital, 19(6): 409 – 413.

Hypertension, 19(5): 359 – 362.

Hypoglycemia, 19(2): 82 – 86.

Icterus, 19(5): 323 – 328.

Idiopathic, 19(4): 275 – 281.

Immunohistochemistry, 19(10): 680 – 686; 19(4): 297 – 299.

Implementation, 19(1): 16 – 22.

Inappropriate care, 19(9): 639 – 644.

Incidence, 19(1): 57 – 63.

Incidental mass, 19(1): 78 – 79.

Index, 19(11): 791 – 796.

Inequality, 19(2): 110 – 115.

Infant, 19(5): 312 – 316.

Inguinal hernia, 19(5): 376 – 378.

Insulin resistance, 19(9): 631 – 638.

Insulin, 19(2): 82 – 86.

Intellectual disability, 19(5): 363 – 375.

Intensive care unit, 19(3): 179 – 185.

Internalizing, 19(1): 51 – 56.

Intra nuclear groove, 19(2): 150 – 152.

Intra nuclear pseudo inclusion, 19(2): 150 – 152.

Intracranial arterial stenosis, 19(5): 317 – 322.

Intrapancreatic accessory spleen, 19(11): 816 – 819.

Inulin, 19(2): 92 – 95.

Iran, 19(1): 2 – 15; 19(1): 57 – 63; 19(10): 680 – 686; 19(10): 720 – 728;

19(10): 729 – 734; 19(10): 747 – 750; 19(11): 762 – 767; 19(11): 768 – 773;

19(11): 797 – 804; 19(11): 820; 19(12): 838 – 844; 19(12): 861 – 865; 19(2):

110 – 115; 19(2): 153 – 162; 19(2): 96 – 100; 19(4): 236 – 240; 19(4): 241 –

247; 19(4): 288 – 294; 19(5): 323 – 328; 19(5): 329 – 334; 19(6): 382 – 387;

19(6): 397 – 402; 19(8): 571 – 576; 19(8): 608 – 609.

Iranian population, 19(11): 774 – 778.

IrSeed-125, 19(3): 186 – 191.

Journal club, 19(8): 556 – 560.

K562, 19(11): 779 – 785.

Kala-azar, 19(2): 153 – 162.

Karyotype, 19(5): 379 – 380.

Kickback, 19(12): 861 – 865.

KIND1 gene, 19(6): 403 – 408.

Kindler syndrome, 19(6): 403 – 408.

Lactobacillus paracasei TD3, 19(2): 92 – 95.

Laparoscopic, 19(1): 57 – 63.

Laparoscopy, 19(1): 78 – 79; 19(3): 173 – 178.

Laparotomy, 19(2): 147 – 149.

Laser lithotripsy, 19(11): 786 – 790.

Latent class analysis, 19(11): 791 – 796.

Late-onset, 19(12): 866 – 869.

Leiomyomatosis, 19(2): 147 – 149.

LESS, 19(1): 57 – 63.

Leukemia, 19(1): 75 – 77.

Lewis phenotypes, 19(1): 35 – 38.

Lewy body disease, 19(6): 449 – 452.

Life style score, 19(11): 752 – 761.

Lung transplantation, 19(4): 262 – 268.

Lung, 19(2): 150 – 152.

Magnetic resonance angiography, 19(1): 72 – 74.

Malaria, 19(4): 241 – 247.

Male infertility, 19(4): 275 – 281.

Mammography, 19(11): 812 – 815.

Marginal effect, 19(9): 666 – 670.

Masticatory function, 19(2): 123 – 130.

Maxilla, 19(3): 221 – 224.

Measles, 19(6): 382 – 387.

Medical ethics, 19(12): 861 – 865.

Medical students, 19(6): 439 – 445.

Medicine, 19(11): 820.

Menopause, 19(2): 141 – 146.

Mental health services, 19(11): 797 – 804.

Mental health, 19(11): 797 – 804.

Mesenchymal stem cell, 19(2): 131 – 136.

Mesenchymal stem cells, 19(8): 561 – 570; 19(8): 584 – 587.

Meta-analysis, 19(1): 57 – 63; 19(4): 288 – 294.

Metabolic status, 19(10): 687 – 692.

Metabolic syndrome, 19(1): 46 – 50; 19(2): 110 – 115.

Metabolic syndrome, 19(4): 269 – 274; 19(8): 577 – 583.

Metanalysis, 19(6): 430 – 438.

Microbiota, 19(3): 197 – 203.

microRNAs, 19(6): 420 – 425.

Minigenome, 19(5): 335 – 341.

miR-100, 19(9): 645 – 651.

miR-182, 19(9): 645 – 651.

Mitotane, 19(9): 671 – 673.

Model-based standardization, 19(9): 666 – 670.

Monosomy, 19(5): 379 – 380.

Monte Carlo simulation, 19(3): 186 – 191.

Mortality, 19(11): 752 – 761; 19(3): 179 – 185; 19(4): 241 – 247; 19(9): 618– 624.

Motivation, 19(10): 704 – 711.

MRI T2*, 19(2): 96 – 100.

Mucous cell, 19(3): 221 – 224.

Multinucleation, 19(8): 584 – 587.

Multiple calculi, 19(11): 786 – 790.

Multiple sclerosis (MS), 19(12): 852 – 860.

Multiple streams, 19(1): 16 – 22.

Multiple trauma, 19(3): 215 – 220.

Mutation spectra, 19(10): 720 – 728.

Mutation, 19(6): 403 – 408.

Myopathy, 19(2): 87 – 91.

NAFLD (Nonalcoholic Fatty Liver Disease), 19(4): 282 – 284.

NASBOD, 19(5): 329 – 334.

Neonatal septicemia, 19(12): 866 – 869.

Neoplasm metastasis, 19(11): 812 – 815.

Nephrectomy, 19(10): 712 – 714.

Newborn, 19(5): 323 – 328.

NF-􀟢B1 and NF-􀟢BIA Polymorphisms, 19(4): 275 – 281.

Non-alcoholic fatty liver disease, 19(10): 693 – 699; 19(9): 631 – 638.

Nonalcoholic steatohepatitis, 19(3): 197 – 203.

Non-Hodgkin’s lymphoma, 19(4): 297 – 299.

Non-secretor status, 19(1): 35 – 38.

Nosocomial infection, 19(3): 179 – 185.

Nursing, 19(6): 439 – 445.

Nutrition, 19(4): 288 – 294.

Obesity indices, 19(2): 110 – 115.

Obesity indices, 19(5): 348 – 352.

Obesity, 19(3): 210 – 214; 19(6): 397 – 402.

OCDUS, 19(9): 659 – 665.

Odontogenic cyst, 19(3): 221 – 224.

Oligospermic, 19(4): 275 – 281.

Omega-3, 19(5): 342 – 347.

o-Q10, 19(8): 588 – 596.

Oral lichen planus, 19(1): 35 – 38.

Overweight, 19(3): 210 – 214; 19(5): 342 – 347.

PAB, 19(5): 348 – 352.

Pain, 19(3): 173 – 178.

Painting, 19(1): 51 – 56.

Palmaris profundus, 19(4): 285 – 287.

Pancreas, 19(1): 30 – 34.

Pancreatic neoplasm, 19(4): 248 – 256.

Pancreatic neuroendocrine tumors, 9(11): 816 – 819.

Parametric g-formula, 19(9): 666 – 670.

Parasite, 19(8): 608 – 609.

Parkinson, 19(8): 561 – 570.

Parkinson’s disease, 19(2): 101 – 109.

Patient outcome assessment, 19(3): 215 – 220.

PCR-SSCP, 19(6): 403 – 408.

Percutaneous transluminal angioplasty, 19(5): 317 – 322.

Perforated, 19(1): 57 – 63.

Pericarditis, 19(9): 674 – 676.

Perinatal, 19(5): 312 – 316.

Peripheral arterial disease, 19(6): 388 – 396.

Persian, 19(9): 659 – 665.

Persistent median artery, 19(4): 285 – 287.

Phototherapy, 19(5): 323 – 328.

Physical activity, 19(8): 530 – 537.

Pioglitazone, 19(2): 131 – 136.

piwil2, 19(6): 420 – 425.

Plasma cell, 19(1): 75 – 77.

Platelet transfusion,19(6): 426 – 429.

Pneumatic lithotripsy, 19(11): 786 – 790.

Point prevalence, 19(3): 204 – 209.

Policy actors, 19(1): 16 – 22.

Policy making, 19(12): 832 – 837.

Policy triangle, 19(1): 16 – 22.

PolyIran study, 19(8): 551 – 555.

Post-endoscopic retrograde, 19(8): 538 – 543.

Postmenopausal women, 19(12): 845 – 851.

Prebiotic, 19(2): 92 – 95.

Preeclampsia, 19(1): 57 – 63.

Pregnant, 19(10): 687 – 692.

Preterm, 19(5): 323 – 328.

Prevalence, 19(1): 2 – 15; 19(1): 64 – 71; 19(12): 838 – 844.

Primary health care (PHC), 19(1): 16 – 22.

Principal components analysis, 19(11): 791 – 796.

Probiotic, 19(10): 687 – 692; 19(2): 92 – 95.

Probiotics, 19(4): 282 – 284.

Prognosis, 19(9): 645 – 651.

Progressive external ophthalmoplegia, 19(2): 87 – 91.

Propensity scores, 19(9): 666 – 670.

Prophylaxis, 19(3): 204 – 209.

Prospective Cohort Study, 19(4): 248 – 256.

Protozoa, 19(8): 608 – 609.

Pseudomonas aeruginosa, 19(5): 353 – 358.

Psychological problems, 19(1): 51 – 56.

Ptosis, 19(2): 87 – 91.

Quality control, 19(8): 551 – 555.

Quality of life, 19(8): 577 – 583.

Questionnaire, 19(9): 659 – 665.

R Programming Language Software, 19(2): 101 – 109.

Rabies virus, 19(5): 335 – 341.

Radiofrequency ablation, 19(9): 671 – 673.

Radiofrequency, 19(5): 348 – 352.

Ratio risk, 19(9): 618 – 624.

Red meat, 19(4): 248 – 256.

Referral, 19(1): 16 – 22.

Reliability and validity, 19(12): 824 – 831.

Reliability, 19(10): 704 – 711; 19(8): 551 – 555.

Repair, 19(9): 612 – 617.

Repeated injections, 19(6): 388 – 396.

Reproducibility, 19(9): 652 – 658.

Reproductive health, 19(11): 805 – 811.

Research, 19(11): 820.

Residency, 19(8): 556 – 560.

Retinol-binding protein 4, 19(12): 845 – 851.

Reverses genetics, 19(5): 335 – 341.

Risk factor, 19(3): 179 – 185; 19(8): 571 – 576.

Risk factors, 19(12): 852 – 860; 19(10): 715 – 719.

Rosso C, 19(12): 886.

Rotavirus, 19(9): 625 – 630.

Saline solution, 19(8): 538 – 543.

Salt reduction, 19(10): 729 – 734.

Sciatic nerve, 19(9): 612 – 617.

Secretor status, 19(1): 35 – 38.

Serum pepsinogen II, 19(2): 137 – 140.

Serum, 19(5): 312 – 316.

Severity score, 19(8): 544 – 550.

Severity, 19(12): 852 – 860.

Sexual behavior, 19(10): 715 – 719.

Sexually transmitted infections (STIs), 19(11): 768 – 773.

Shoulder, 19(3): 173 – 178.

Sialo-odontogenic cyst, 19(3): 221 – 224.

Single factor model, 19(2): 110 – 115.

Single institution’s experience, 19(1): 30 – 34.

Small intestine, 19(2): 92 – 95.

SNP, 19(1): 46 – 50.

Social consequence, 19(11): 805 – 811.

Social determinants of health, 19(1): 39 – 45.

Social justice, 19(1): 39 – 45; 19(10): 735 – 740.

Sociodemographics, 19(10): 715 – 719.

Socioeconomic status, 19(11): 791 – 796; 19(8): 530 – 537.

Sodium selenite, 19(1): 23 – 29.

Solid organ transplant (SOP), 19(10): 700 – 703.

Solid-pseudopapillary tumor, 19(1): 30 – 34.

Sorafenib, 19(9): 671 – 673.

Specialization, 19(1): 39 – 45.

SPECT, 19(6): 449 – 452.

Spot urine, 19(9): 652 – 658.

Staghorn, 19(10): 712 – 714.

Standardization, 19(6): 414 – 419.

Stemline, 19(5): 379 – 380.

Stenting, 19(5): 317 – 322.

  
Privacy Statement    |    Terms Of Use Copyright 2009 by Academy of Medical Sciences of the I.R. Iran